Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcyte vs Neulastim for Chemotherapy-Induced Neutropenia in Breast Cancer
NCT03381417Phase 3Completed
- Sponsor
- Nanogen Pharmaceutical Biotechnology JSC
- Start
- Oct 2016
- Primary completion
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegfilgrastim in chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by Nanogen Pharmaceutical Biotechnology JSC. Primary endpoint: Percentage of patients who developed Febrile neutropenia. Started Oct 2016; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT03381417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381417.